

Omega Pharma NV

Number of shares and shareholder's equity

The Company's shareholder's equity on 1 January 2007 was 16,315,105.61 euro and was represented by 26,984,681 shares. On 31 December 2007 this was 16,450,190.62 euro represented by 26,205,848 shares. On 31 March 2008 the shareholder's equity amounted to 16,451,521.34 euro represented by 26,207,968 shares.

The changes that have occurred in this period are explained by the following notary acts:

- 5 February 2007: creation of 8,750 new shares due to the exercise of warrants, thus bringing the total number of shares to 26,993,431 and corresponding capital increase within the authorised capital bringing the shareholders' equity to 16,320,395.61 euro and the issue premium to 342,061,285.85 euro.
- 5 February 2007: creation of 153,210 new shares due to the exercise of warrants, thus bringing the total number of shares to 27,146,641 and corresponding capital increase within the authorised capital bringing the shareholders' equity to 16,413,026.28 euro and the issue premium to 348,186,810.08 euro.
- 9 March 2007: cancellation of 1,000,000 treasury shares without capital decrease, thus bringing the total number of shares to 26,146,641. The shareholders' equity remained unchanged.
- 6 July 2007: creation of 49,907 new shares due to the exercise of warrants, thus bringing the total number of shares to 26,196,548, and corresponding capital increase within the authorised capital bringing the shareholders' equity to 16,444,353.00 euro and the issue premium to 349,472,778.15 euro.
- 7 September 2007: creation of 6,250 new shares due to the exercise of warrants, thus bringing the total number of shares to 26,202,798 and corresponding capital increase within the authorised capital bringing the shareholders' equity to 16,448,276.13 euro and the issue premium to 349,767,064.40 euro.
- 7 December 2007: creation of 3,050 new shares due to the exercise of warrants, thus bringing the total number of shares to 26,205,848 and corresponding capital increase within the authorised capital bringing the shareholders' equity to 16,450,190.62 euro and the issue premium to 349,884,137.56 euro.
- 6 February 2008: creation of 2,120 new shares due to the exercise of warrants, thus bringing the total number of shares to 26,207,968 and corresponding capital increase within the authorised capital bringing the shareholders' equity to 16,451,521.34 euro and the issue premium to 349,923,659.73 euro.

The most recent situation can always be found at the corporate website (www.omega-pharma.be), in the Investor Centre, under the header Info for shareholders.